The continual reassessment method (CRM) is an increasingly popular approach for estimating the maximum tolerated dose (MTD) in phase I dose finding studies. In its original formulation, the scheme is based on a fixed sample size. Many experimenters feel that, whenever possible, it may be advantageous to bring these trials to an early halt and thus reduce average sample size required to complete the study. To address this issue a stopping rule has been proposed (O'Quigley and Reiner, 1998) based on the idea that continuing the study would not lead to a change in recommendation with high probability. The rule, based on precise probabilistic calculation, is quite involved and not straightforward to implement. A much simpler rule can be constructed based on the idea of having settled at some level. In this work we investigate more deeply the essential ingredients behind these rules and consider more closely their operating characteristics.
INTRODUCTION
The continual reassessment method (CRM) (O'Quigley et al., 1990; Storer, 1998 ) is a sequential design for estimating the maximum tolerated dose (MTD) in phase I studies. The main feature of the design is that of sequential updating of the current estimate of the MTD, using all included patients, and based on the use of a single-parameter dose-toxicity working model. The model provides the current estimates of the toxicities at each of the available doses. Each included patient, or cohort of included patients, is treated at the dose estimated to be the closest to the MTD. A fixed sample size n is decided upon for the study and the estimated MTD is the dose that would be allocated to patient n + 1 were they to be included in the trial. It may be felt that phase I trials should be halted early whenever possible. The concern is to quickly proceed to the phase II trial. This is especially true in oncology where lengthy phase II studies of response may be required in order to determine any potential efficacy of experimental treatments.
In an attempt to deal with these concerns, some stopping rules have been proposed that would allow for the early termination of the phase I trial (O'Quigley et al., 1990; O'Quigley and Reiner, 1998; Heyd and Carlin, 1999) . The rule suggested by O'Quigley et al. (1990) , later given a theoretical justification by Shen and O'Quigley (1996) and further studied by Heyd and Carlin (1999) , decides on the basis of a confidence interval whether enough precision has been obtained to bring the study to an early close. There are two drawbacks to this approach. Firstly, most commonly accepted levels of precision would typically require many more patients than are likely to be available so that, in practice, the trial is not likely to halt before the maximum number of patients has been included under a fixed-sample scheme. Secondly, it is not clear that obtaining some fixed level of precision for the probability of toxicity at the recommended dose is of itself a major concern. The MTD will correspond to some point percentile but, in practice, there is quite some room for flexibility around this point.
The starting point of O'Quigley and Reiner (1998) was a fixed-sample study. We have in mind some upper limit to the number of patients we aim to include. If, before all patients have been included, we can predict with high probability what the final recommendation will be, then we bring the study to a close. The principle behind the method stems from the property of the CRM to converge to some level and then to include the remaining patients at this same level. This property suggests a yet simpler rule; keeping track of the number of times each of the available doses is used during the trial and taking as stopping condition the following: stop when the dose recommended to the next patient has already been allocated m times, where m is some number fixed at the beginning of the trial. This has the advantage of great simplicity and, as we see below, works out quite well in practice.
The goal of this paper is to give further consideration to these rules and to compare their operational characteristics in practical settings.
BACKGROUND AND NOTATION
We assume that we have available k doses; d 1 , . . . , d k , ordered in terms of the unknown true probabilities, R(d i ), for toxicity at each of the levels. The most appropriate dose, the 'target' dose, is that dose having an associated probability of toxicity as close as we can get to some target 'acceptable' toxicity θ. This is our definition of the MTD. The dose for the jth entered patient, X j can be viewed as random taking values x j ∈ {d 1 , . . . , d k }; j = 1, . . . , n. The recommended dose is called x R where we can take R = n + 1, although no more than n patients are actually treated. Let Y j be a binary random variable (0, 1) where 1 denotes severe toxic response for the jth entered patient ( j = 1, . . . , n). We model R(x j ), the true probability of toxic response at
for some one-parameter model ψ(x j , a) and a defined on the set A. Restrictions on ψ(x, a) were described by O'Quigley et al. (1990) . We have a lot of flexibility in our choice for ψ(x, a), the simple choice
where 0 < α 1 < · · · < α k < 1 and −∞ < a < ∞, having worked well in our experience. For the six levels studied in the simulations by O'Quigley et al. (1990) the working model had α 1 = 0.05, α 2 = 0.10, α 3 = 0.20, α 4 = 0.30, α 5 = 0.50 and α 6 = 0.70. Once a model has been chosen and we have data in the form of the set j = {y 1 , x 1 , . . . , y j , x j }, the outcomes of the first j experiments, we obtain estimateŝ . . . , k) at the k dose levels (see below). The target dose level is that level having associated with it a probability of toxicity as close as we can get to θ. The dose or dose level x j assigned to the jth included patient is such that
After the inclusion of the first j patients, the log-likelihood can be written as
and is maximized at a =â j . Once we have calculatedâ j we can next obtain an estimate of the probability of toxicity at each dose level
On the basis of this formula the dose to be given to the ( j + 1)th patient, x j+1 is determined. In the early work of O'Quigley et al. (1990) , Bayesian estimates were used. These follow from simply putting some prior, most often non-informative, on a. We denote this g (a) . In this context the starting level
This may be a difficult integral equation to solve and, practically, we might take the starting dose to be
Given the set j the posterior density for a is
The dose x j+1 ∈ {d 1 , . . . , d k } assigned to the ( j + 1)th included patient is the dose minimizing the Euclidean distance between θ and ψ{x j+1 , u} f (u| j ) du. Often it will make little difference if, rather than work with the expectations of the toxicities, we work with the expectation of a, thereby eliminating the need for k − 1 integral calculations. Thus we treat the ( j + 1)th included patient at level
Motivation for early termination
One of the particularities of the CRM is the property of convergence. It is shown in Shen and O'Quigley (1996) that if the chosen working model satisfies certain broad conditions then the method will converge almost surely to the level where the toxicity is closest to the targeted MTD. This result is extended in O' Quigley and Reiner (1998) where it is shown that almost sure convergence to some level, close if not the closest, is assured under very broad conditions. Two examples, both using the working model of the above section, are illustrated in Figure 1 . For the first the true probabilities of toxicity were 0.10, 0. 
STOPPING RULE BASED ON CONFIDENCE INTERVALS
For completeness we summarize a rule, alluded to by O'Quigley et al. (1990) and O'Quigley (1992) and studied more fully by Heyd and Carlin (1999) . We do not study it in any more depth here. Once we have estimated a we can also calculate an approximate 100 where z α is the αth percentile of a standard normal distribution and v(â j ) is an estimate of the variance ofâ j . For the model of (1) this turns out to be particularly simple and we can write
Although based on a misspecified model these intervals turn out to be quite accurate, even for sample sizes as small as 16, and thus helpful in practice (O'Quigley, 1992) . In the Bayesian setting, apart from choices of prior, there is more than one way to proceed. After the inclusion of the jth patient, we can estimate the variance of a via σ
Under our prior distributional assumption for a we can then calculate an 100(1 − α)% confidence interval for a, with a + j and a − j as lower and upper confidence limits, respectively. An alternative approach is to calculate an approximate 100
As the large-sample normal approximation becomes more accurate the two approaches lead to the same intervals. We can use the confidence interval (a
for a in order to find the limiting percentiles required. The stopping rule amounts to bringing the study to a halt once the interval for θ is contained in some prespecified range, say (θ − θ − ; θ + θ + ) for some θ − and θ + chosen by the investigator. Note that, for j = n, we can show the large-sample accuracy of these intervals in terms of reproducing the correct coverage probabilities . For finite samples (n = 20 or more), under a range of miss-specified models the intervals appear accurate enough for practical purposes (O'Quigley, 1992) . However, as soon as we wish to use these intervals as a guide to early stopping, we will most likely use them at more than one value of j. If a solid confidence interval interpretation is being sought, in most cases the user would wish for it to refer to the simultaneous coverage at the collected values of j where the calculations are carried out. We do not have this interpretation here and to achieve it would require quite some work, involving the correlation structure across the different values of j. A potential avenue for exploration could then be the construction of effective sequential adjustments in order to maintain approximately correct coverage. I feel unenthusiastic about such a venture for two reasons; the correlations are high enough that ignoring them may make little practical difference and, secondly, the rule is to be judged essentially in the context of achieving the goals of a phase I/II dose finding design, its ability to accurately reproduce nominal error rates being very much a secondary issue. A more interesting approach to the problem could be constructed on the basis of the observation that our designs, whether Bayesian or likelihood, translate the idea of the steady growth in information. This information, indirectly indexed by j, enables us to learn about the location and the dispersion of responses. Under orthogonality conditions, i.e. the usual linear model, we can nicely separate out location from dispersion. Under binomial sampling this is no longer possible, the two quantities being intertwined. Some recent work on the role of pilot studies (Wittes and Brittain, 1990; Birkett and Day, 1994 ) may provide insight into our problem, the model miss specification not necessarily being a major difficulty due to most experimentation being carried out at a single level.
STOPPING RULE BASED ON BINARY OUTCOME TREES
In the light of Figure 1 , if given enough time, any trial will present a similar picture: early oscillation followed by a more or less long plateau. The dose recommended at the end of the plateau is the MTD. One idea studied by O'Quigley and Reiner (1998) was to consider to what extent we could anticipate at some earlier point of the plateau that we were indeed on a plateau. In some cases this can be stated with certainty, i.e. whatever happens to the remaining patients in the study the level will not change. More generally we can say something about the probability of staying and remaining at some level for the remainder of the study. There are two probabilities of potential interest: the probability that the dose recommended after the inclusion of all n patients be the same as that recommended after the inclusion of j patients and the probability of the more restrictive event in which, not only are the recommendations following j and n inclusions the same, but all inclusions between j and n have the same level. This second probability corresponds more closely to the idea of having converged to some level. We denote these probabilities by:
Thus, P 1 ( j) is the probability that the recommended dose level at the end of the study is x j . P 2 ( j), on the other hand, is the probability that x j will be the final recommended dose and that all patients succeeding the jth patient will be treated with this dose. Since P 1 ( j) and P 2 ( j) depend on the true dose toxicities which are unknown, we can only estimate these probabilities. Consistent estimation is possible for P 2 ( j) under the broad conditions described by Shen and O'Quigley (1996) . For P 1 ( j) consistent estimation is only possible when the working model coincides with the true mechanism generating the toxicities. This is much more restrictive than what we usually wish to suppose in the context of CRM models. Nonetheless, we can proceed with the development of estimates for P 1 ( j), under these restrictive assumptions, and then investigate how they perform in practice under more realistic conditions. This is done below. Performance is in fact quite good although, lacking the firmer theoretical footing we can give to P 2 ( j), we may wish to treat these estimates with somewhat more circumspection. The estimates in both cases are obtained using the following algorithm. First, one constructs a binary tree of all possible outcomes of the trial between patient j and patient n + 1. Then, we adopt the following notation: C 1 ( j) is the set of paths in the tree for which the level recommended to subject n + 1 is the same as the level that has been recommended to subject j, C 2 ( j) is the set of paths in the tree that represents no change in level for the last n − j subjects and |c| is the number of toxicities encoded by a path c ∈ C 1 ( j) or c ∈ C 2 ( j). With this notation we have
This quantity is consistently estimated bŷ
wherep j = ψ(x j+1 ,â j ), the estimated probability of toxicity of the level recommended to patient j + 1. We can useP ( j) in the following way. A minimum number of patients j 0 ( j 0 < n) is included in the trial. Once this lower bound on the sample number is reached,P ( j) is computed for each new patient. We stop including patients as soon asP ( j) > p 0 , where p 0 is a minimum probability set in advance.
The estimatesP 1 ( j) andP 2 ( j) are obtained in conjunction with the construction of the binary tree of all possible outcomes of the study following treatment of the ( j + 1)th patient. More precisely, the following algorithm is adopted:
1. Labels the root of the tree with the dose number recommended to the ( j + 1)th patient. 2. Label the left child of the root with the dose recommended to the ( j + 2)th patient if the ( j + 1)th patient experiences a toxicity. 3. Label the right child of the root with the dose recommended to the ( j + 2)th patient if the ( j + 1)th patient experiences no toxicity. 4. Continue filling in the tree as in steps 1 and 2 until all patients to be included in the trial are exhausted.
Once this binary tree is constructed we useâ j , our current estimate of a, to estimate the toxicitieŝ p j+1 , . . . ,p n . These in turn allow us to assign probabilities to each binary path in the tree and thus calculate the probabilitiesP 1 ( j) andP 2 ( j) by considering paths in the tree corresponding to no change in dose level. We illustrate this algorithm with an example. Let us suppose that 12 patients have been included in the trial and we do not yet have the response for the 12th patient. Let us suppose there are six dose levels and that the chosen model is to be as in Section 2. Additionally, in a Bayesian setting, we assume a normal prior distribution for the parameter a (O'Quigley, 1992), g(a) = 0.21 exp{−(a/1.9) 2 }. Consider the sequence of events in Table 1 where a 1 indicates a toxicity and a 0 indicates a non-toxicity. We construct the tree of possible events that can occur after administering dose 2 to patient 12. The circled number in each node represents the dose that would be recommended after the sequence of responses preceding that node in the tree. Thus, for example, we would recommend dose 1 to patient 13 if patient 12 suffered a toxicity and dose 2 otherwise. Using the estimateâ 11 = −0.38, we now estimate the probabilities of toxicities and non-toxicities for each dose level. We are now ready to assign values to each binary path in the tree using the probabilities from Table 2 . We are now in a position to compute the probabilities:
We can assess the average sample saving for any given situation. In practice we know little about the type of situation that we anticipate encountering but we can give consideration to different classes of situations. To consider the very broadest classes would be time consuming but it can still be very helpful, at least in terms of tying down parameters, to study the effects for some given cases. This corresponds to the kind of work we do in power calculations for randomized studies. A table, summarizing a range of possible dose-toxicity curves, labeled situations A to S, is presented toward the end of this section.
Simulating from this class, each member being chosen with the same probability, enables some broad cases to be covered. We did this for a maximum sample of 20 and for two values of p 0 . The results in terms of the cumulative distribution of sample size is presented in Figure 2 . Such information may be helpful in making choices on trial design and in selecting an appropriate value of p 0 to work with. The potential trade-off between, on the one hand, sample size gains and, on the other, reductions in the precision of a determination on the level we would eventually settle at, were all twenty patients to be studied, is then brought into sharp focus.
Precision of estimates
Approximate confidence intervals for these estimators can be obtained in the following way. We can use (a
for P 1 and P 2 , respectively. An estimate is obtained by recalculating the probabilitiesp j+1 , . . . ,p n using a + j , re-labeling the binary tree with these new probabilities and then computingP 1 andP 2 to get P L 1 and P L 2 . One then repeats this process with a − j to get the other endpoints of the confidence intervals. Such a procedure would maintain the coverage properties of (a + j , a − j ) of a forP 1 andP 2 if these were monotonic functions. This will be true in some but not all situations. We therefore need to employ slightly more sophisticated tactics to obtain the desired intervals in more general situations. Our strategy is to subdivide (a
For eachâ we obtain new values ofP 1 ( j) andP 2 ( j) based onp j+1 , . . . ,p n , as before, re-labeling the binary tree. Taking the maximum and minimum P U 1 and P L 1 of these values (respectively, P U 2 and P L 2 ) one obtains an interval for P 1 (and respectively for P 2 ) which no longer requires the monotonicity assumption. Coverage properties then need to be investigated separately. We illustrate this idea by considering an example. Here, we suppose the working model to be that of Section 2; the maximum sample size n was taken to be 15 and we consider the binary tree (not shown) after seeing the first 10 patients. The initial sequence of toxicity results is 1 0 1 0 0 0 0 0 0 and the estimate of a after observing the 9th patient isâ 10 = −0.36. For clarity, we use M = 4 in this illustration, though one generally takes larger values such as M = 20. From this we can construct Table 3 from which we obtain the confidence intervals of Table 4 . 
Simulation study on precision
To test the reliability of the confidence intervals presented above we ran a series of simulations corresponding to some classes of potential situations. We assumed a CRM phase I trial with a projected maximum number of 25 patients. For each situation below we compute the probabilities P 1 (16) and P 2 (16), that is we calculate these probabilities after including 16 patients in the trial. Table 5 shows a range of situations that we considered for the true probabilities of toxicities. The table corresponds to the class studied by O'Quigley et al. (1990) , the idea being to represent a variety of cases: from steep dose toxicity curves to shallow ones; situations in which the target level is the lowest as well as situations in which the target toxicity level is the highest. It would not be possible to be exhaustive and difficult to come up with realistic representations of the set of dose-toxicity curves existing in nature. This question may be worthy of more investigation, the aim being to claim greater generality for the kind of findings we have here. In the meantime we conjecture that the results do nonetheless have greater generality than simply for the limited number of situations considered.
For each situation, we ran 100 simulations. For each simulation we computed five confidence intervals for P 1 and P 2 as well as the true values of P 1 and P 2 since these can be evaluated. We then consider a confidence interval successful if the value of P 1 falls within the confidence interval for P 1 and similarly for the confidence intervals obtained for P 2 . The results, although limited, do lend support to the theory and allow us to give some interpretation to both the point estimatesP 1 andP 2 as well as the interval estimates. As already stated, the probabilistic interpretation forP 2 is assured under the general conditions outlined in Shen and O'Quigley (1996) whereas the almost comparably good performance ofP 1 is, possibly, surprising. We have not investigated this any more deeply, one conjecture being that, for the inconsistent estimates of toxic probabilities at levels other than the target, they broadly even out, leaving the overall estimate of P 1 satisfactory. In view of the good performance, it seems worth presenting the results for 
STOPPING RULE BASED ON ALLOCATION LIMITS
A collection of events clearly related to those quantified by P 2 ( j) is the number of times any level has been recommended. The more time that is spent at some given level the more likely it is, under CRMtype sequential sampling, that this same level will turn out to be the MTD. This idea is behind the simple stopping rule proposed by Korn et al. (1995) in which, after some fixed number of patients had been treated at some level the study is brought to a close. Intuitively, the idea is to set a maximum number, m, of times any level should be allocated. A trial is halted as soon as this maximum is reached or exceeded by some level. Formally, for each i = 1, . . . , k and j = 1, . . . , n we define the quantity m i j = the number among the first j subjects treated at level d i .
Thus, the m i j keep track of the number of times each of the available levels have been used during the course of the trial. With this notation, termination is called as soon as m i j = m for some j < n and 1 i k. For large m, theoretical justification could follow the same reasoning underlying the rule for binary outcome trees. In practice m will be small, as small as 5 or 6, and so it is more useful to consider behavior via simulations in practical settings. In Figure 3 we can work out the average sample size required under different rules, the chosen cases concerning m = 5 and m = 15. For m = 5 the average sample required is 13.4 and for m = 15 the average sample size required is 27.2. For the same class of situations it is possible to obtain a ready impression of the cost of being more stringent and, for example, as part of initial design exploration, we could table average sample sizes against the value of m, using this information to help select a design. As important, if not more so, as average sample number in fixing design parameters is the accuracy of the decision taken. In Figure 4 , over a very broad class (Paoletti, 2001) we plot accuracy of final recommendation in terms of the cumulative distributions of the recommendation errors. The error is the squared distance of the probability of toxicity at the selected dose from that at the target dose. For m = 15 the error is very close to that obtained from using a fixed-sample CRM with 20 subjects. Since the average sample size is more than this there is not much incentive to use such a stopping rule with m so large. However, for m = 5, although from the figure we clearly lose some accuracy, we do not lose that much accuracy and such figures enable us to quantify the amount. The gains are potentially substantial since average sample size is less than 20. One clear advantage to a rule based on allocation limits is its great simplicity. Once we have fixed m, as an experimental design parameter, no further calculation is needed. This contrasts sharply with the binary outcome tree rule which necessitates involved combinatorial calculation and the inevitable use of computer algorithms.
